reports
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Small Cap Research
- Karl Bokvist
- Nikola Kalanoski
- Simon Jönsson
CTT CTT SYSTEMS AB
PREV B PREVAS B
CATE CATENA AB
GENI GENERIC SWEDEN AB PUBL
DUST DUSTIN GROUP AB
EKTA B ELEKTA AB CLASS B
STEF B STENDOERREN FASTIGHETER AB CLASS B
BONEX BONESUPPORT HOLDING AB
HMS HMS NETWORKS AB
MIPS MIPS AB
BOOZT BOOZT AB
A2DRL9 SDIPTECH AB B
FRACTL FRACTAL GAMING GROUP AB
RUG RUGVISTA GROUP AB
PACT PROACT IT GROUP
SFAB SOLID FORSAKRINGSAKTIEBOLAG
NOLA B NOLATO AB
HEM HEMNET GROUP AB (PUBL)
SLP B SWEDISH LOGISTIC PROPERTY AB
ITECH I-TECH AB
VESTUM VESTUM AB
ACAST-SE ACAST
SECT.B-SE SECTRA
GREEN GREEN LANDSCAPING GROUP AB (PUBL)
- Maria Vara
BONESUPPORT: 2025 Trim; Spine optionality kicks in
Following Q2 earnings, we revisited our expectations across all business segments, leading to a 9% 2025E sales cut, majorly driven by FX headwinds on US sales, while country-specific policies in EUROW led to softer-than-expected H1 growth. Our long-term thesis remains unchanged, and we see improvin
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Q2 US momentum in line; softer EU and FX weigh on EBIT
BONESUPPORT reported Q2 2025 net sales of SEK 284.4m, slightly below CSS SEK 291m (Stifel est. SEK 299m), with the deviation primarily due to a softer-than-expected European performance. Growth was led by the US, which grew 36% YoY reported (49% CER), though it fell -2%, and -4% vs CSS and our expe
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Bonesupport Holding AB: 1 director
A director at Bonesupport Holding AB bought 2,000 shares at 273.000SEK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Q1 revenue beats, but FX-driven EBIT miss masks solid mom...
BONESUPPORT reported a robust Q1, with net sales of SEK283.5m beating CSS SEK276m and driven by CERAMENT G sales of SEK178m in North America — well ahead of the SEK160m forecast. Gross margin remained best-in-class at 92.6%, slightly above expectations, underscoring the strength of the business mod
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Model Update – Reiterate BUY and SEK400 PT
We have updated our model, rolling it over after Q4 results and in preparation for Q1 2025, to be reported on 24 April. While our long-term conviction for BONESUPPORT products has not changed, we have slightly softened our 2025 EU sales growth assumptions from 39% to 22% YoY growth following a slow
- ABGSC Small Cap Research
- Karl Bokvist
- Nikola Kalanoski
- Simon Jönsson
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Closing a solid 2024
2024 saw BONESUPPORT further accelerate its market leadership with Q4 sales reaching SEK257m—up 49% YoY—driving FY sales to SEK898.7m (52% YoY), in line with guidance of 50% topline growth. In North America, CERAMENT G continued its strong performance, rising by approximately SEK22m QoQ to reach ar
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: CERAMENT adverse event clarification amidst market volati...
BONESUPPORT shares have dropped by 15% YTD, driven by profit-taking ahead of FY 2024 earnings on February 25, coupled with concerns over a reported adverse event involving CERAMENT BVF. We believe the market reaction is overblown, largely fueled by retail sentiment. The event resulted from off-labe
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.